Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2020-03-16 Regulatory Filings
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Karolinska Development meddelar nytt datum för årsstämma
Regulatory Filings Classification · 1% confidence The document is a short press release (2105 characters) from Karolinska Development announcing a change in the date for the Annual General Meeting (årsstämma) from May 7th to June 15th, 2020, due to COVID-19. It explicitly states that the formal notice ('Kallelse till årsstämman') will be published later in a separate press release. Since this document is an announcement about scheduling an AGM, rather than the AGM materials themselves (AGM-R) or the formal notice (which would likely be DEF 14A or PSI), and given its nature as a brief update regarding a shareholder meeting, it most closely aligns with an announcement related to corporate governance or a general regulatory update. However, the core subject is the AGM date change. While 'AGM-R' is for the materials, this is a pre-announcement. Given the options, and recognizing that AGMs are central shareholder events, this is a specific announcement related to the AGM process. Since there isn't a specific code for 'AGM Date Change Announcement', and it's not the final proxy or the meeting materials, it falls best under a general regulatory announcement or a governance-related item. Given the strong focus on the 'årsstämma' (AGM), and the fact that it is a formal communication about the meeting schedule, it is highly related to AGM information. However, based on the strict definitions, it is not the AGM materials (AGM-R) or the proxy (PSI). It is an announcement about the meeting. If we treat it as a general regulatory announcement about a key corporate event, RNS is a possibility. If we consider it preparatory information for the AGM, it relates to AGM-R. Given the context of corporate actions, and the short length, it is most likely a Report Publication Announcement (RPA) if it were announcing the publication of the formal notice, but here it announces the *date change*. Since it is a formal announcement regarding a key shareholder event (AGM), and it is not the final materials, the closest fit among the specific codes related to shareholder meetings is AGM-R, although it is a precursor. Given the options, and the subject matter being the AGM, I will classify it as AGM-R as it pertains directly to the AGM event, even if it's just the date change announcement, as it's more specific than RNS or RPA.
2020-03-16 Swedish
Karolinska Development appoints Johan Dighed as General Counsel
Board/Management Information Classification · 1% confidence The document is a press release announcing a specific personnel change: the appointment of Johan Dighed as General Counsel and the retirement of the previous counsel. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information' (MANG). The document is short and clearly structured as an announcement, not a comprehensive financial report.
2020-03-09 English
Karolinska Development utser Johan Dighed til Chefsjurist
Board/Management Information Classification · 1% confidence The document is a press release dated March 9, 2020, announcing the appointment of Johan Dighed as Chief Legal Counsel (Chefsjurist) and his start date, replacing the retiring Ulf Richenberg. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information' (MANG). The document is short and clearly an announcement, not a comprehensive report.
2020-03-09 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for Karolinska Development, covering the fourth quarter and the full fiscal year 2019. It includes detailed financial data such as net results, earnings per share, portfolio valuations, revenue, and cash flow, as well as a CEO report and management commentary on business trends and outlook. It is not a mere announcement or certification, but a substantive financial report for a period shorter than a full fiscal year (in the context of the Q4/Full Year reporting cycle). Q4 2019
2020-02-13 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 1% confidence The document provides a detailed financial summary for the fourth quarter and full year 2019, including net profit/loss, earnings per share, portfolio fair value, and cash flow analysis. It also includes a 'Chief Executive's Report' and a list of significant events. Because it contains comprehensive financial statements and analysis for a period shorter than a full fiscal year (Q4 and full year 2019), it is classified as an Interim/Quarterly Report. Q4 2019
2020-02-13 English
Karolinska Developments portföljbolag Aprea Therapeutics erhåller FDA Breakthrough Therapy Designation
Regulatory Filings Classification · 1% confidence The document is a press release from Karolinska Development AB announcing that its portfolio company, Aprea Therapeutics, received Breakthrough Therapy Designation from the FDA for a drug candidate. This announcement concerns a specific regulatory event (FDA designation) related to drug development, which is a form of corporate news. It is not a full Annual Report (10-K), an Interim Report (IR), an Earnings Release (ER), or a formal Audit Report (AR). Since it is a specific announcement about a regulatory/development milestone, it fits best under the general 'Regulatory Filings' (RNS) category as a significant corporate update that doesn't fit the other specific categories like Director's Dealing (DIRS) or Capital Change (CAP). Given the content is a direct announcement of a regulatory action, RNS is the most appropriate general regulatory filing category.
2020-01-30 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.